주의력결핍 과잉행동장애(ADHD) 신규 치료법 보고서(2026년)(2분기판)

The Global Attention Deficit Hyperactivity Disorder (ADHD) Emerging Therapies Market is projected to grow at a CAGR of 10.4% during the forecast period, increasing from USD 0.91 billion in 2026 to USD 2.21 billion by 2035.

The global attention deficit hyperactivity disorder (ADHD) emerging therapies market is witnessing significant expansion as pharmaceutical companies, biotechnology firms, academic institutions, and neuroscience research organizations accelerate the development of next-generation treatment options. Emerging therapies analysis provides comprehensive insights into investigational drugs, novel mechanisms of action, clinical development progress, pipeline maturity, licensing activities, regulatory milestones, and commercialization opportunities. As unmet clinical needs persist despite the widespread use of stimulant medications, developers are increasingly focusing on innovative therapies that offer improved efficacy, enhanced safety, longer duration of action, and reduced abuse potential.

Current ADHD treatment continues to rely primarily on stimulant medications and a limited number of non-stimulant therapies. Although these treatments are effective for many patients, concerns related to adverse effects, cardiovascular safety, appetite suppression, sleep disturbances, treatment adherence, and misuse continue to drive research into alternative therapeutic approaches. Emerging therapies include selective neurotransmitter modulators, novel non-stimulant compounds, long-acting formulations, precision medicine approaches, digital therapeutics, neurostimulation technologies, and combination treatment strategies designed to address the diverse needs of pediatric, adolescent, and adult patients.

The therapeutic landscape is also benefiting from advances in neuroscience, genomics, artificial intelligence, and biomarker research. These technologies are improving target identification, patient stratification, clinical trial design, and prediction of treatment response. Digital health solutions, wearable monitoring devices, electronic patient-reported outcomes, and decentralized clinical trials are further enhancing the efficiency of therapeutic development while generating high-quality real-world evidence to support regulatory and commercial decision-making.

Growing awareness of ADHD across all age groups, increasing diagnosis rates, expanding healthcare expenditure, and rising investment in central nervous system research continue to strengthen the global emerging therapies landscape. Strategic collaborations between pharmaceutical companies, biotechnology innovators, research institutions, and technology providers are accelerating development timelines while creating new opportunities for differentiated therapies. As several promising candidates advance through clinical development, emerging therapies are expected to reshape the future ADHD treatment landscape during the forecast period.

Market Drivers

Increasing Demand for Novel Therapeutic Options

Limitations associated with conventional stimulant medications continue to create demand for innovative therapies with improved safety, lower abuse potential, and enhanced patient adherence.

Developers are actively investigating non-stimulant compounds, novel pharmacological targets, and personalized treatment approaches capable of addressing unmet clinical needs.

Expansion of Non-Stimulant Drug Development

The growing interest in non-stimulant therapies has accelerated research into selective neurotransmitter modulators and alternative mechanisms of action.

These therapies aim to provide effective symptom control while minimizing adverse effects commonly associated with stimulant medications.

Advances in Digital and Device-Based Therapies

Digital therapeutics, cognitive training platforms, wearable technologies, and neurostimulation devices are emerging as complementary or alternative treatment options.

These innovations provide individualized treatment approaches while expanding therapeutic options beyond conventional pharmacological interventions.

Growing Investment in Neuroscience Research

Governments, pharmaceutical companies, venture capital firms, and academic institutions continue to increase investment in neurodevelopmental disorder research.

Rising research funding is accelerating target discovery, translational medicine, and advancement of promising pipeline candidates through clinical development.

Adoption of Precision Medicine

Advances in genetics, biomarkers, and artificial intelligence are supporting personalized ADHD treatment strategies.

Precision medicine enables improved patient selection, optimized therapeutic response, and more efficient clinical development programs.

Market Restraints

Lengthy Clinical Development Timelines

Emerging ADHD therapies require extensive clinical evaluation to demonstrate long-term efficacy, safety, and tolerability.

Lengthy development programs may delay regulatory approval and commercialization.

High Research and Development Costs

Discovery research, multicenter clinical trials, regulatory submissions, and manufacturing optimization require substantial financial investment.

Smaller biotechnology companies often rely on licensing agreements or strategic partnerships to advance promising candidates.

Regulatory and Safety Requirements

Novel ADHD therapies must satisfy rigorous regulatory standards regarding efficacy, abuse liability, cardiovascular safety, and long-term clinical outcomes.

These requirements increase development complexity and commercialization risk.

Technology and Segment Insights

By Development Phase

Phase II clinical trials represent a substantial portion of the emerging therapy pipeline as developers evaluate optimal dosing, efficacy, pharmacokinetics, and safety.

Phase III programs continue to expand as advanced candidates progress toward regulatory submission, while preclinical and Phase I research remains active through continuous introduction of innovative therapeutic mechanisms.

By Therapy Type

Small-molecule therapies continue to dominate the emerging pipeline because of established manufacturing processes and favorable pharmacological characteristics.

Non-stimulant medications represent one of the fastest-growing segments as developers seek alternatives with improved tolerability and lower abuse potential.

Digital therapeutics, neurostimulation devices, and combination therapies are also expanding rapidly as complementary treatment options for ADHD management.

By Mechanism of Action

Emerging therapies increasingly target multiple neurological pathways beyond traditional dopaminergic and noradrenergic systems.

Developers are evaluating selective receptor modulators, innovative neurotransmitter targets, and precision medicine approaches designed to improve therapeutic outcomes while minimizing adverse effects.

By End User

Pharmaceutical companies remain the largest participants in emerging therapy development due to sustained investment in drug discovery, clinical research, and commercialization.

Biotechnology companies continue to expand their presence through development of first-in-class therapies and innovative technology platforms.

Academic institutions, contract research organizations, and neuroscience research centers also contribute significantly through early-stage discovery, translational research, and collaborative clinical programs.

Regional Insights

North America dominates the global ADHD emerging therapies market due to its advanced pharmaceutical industry, robust biotechnology ecosystem, strong neuroscience research capabilities, and supportive regulatory environment. The United States remains the leading center for ADHD therapeutic innovation, hosting numerous investigational programs and strategic collaborations.

Europe represents another important market supported by collaborative academic research, established pharmaceutical companies, and increasing investment in neurodevelopmental disorders. Countries including Germany, the United Kingdom, France, Italy, and Spain continue to participate actively in multinational clinical development programs.

Asia Pacific is expected to record the fastest growth during the forecast period. Expanding healthcare infrastructure, increasing pharmaceutical research investment, improving regulatory pathways, and growing awareness of ADHD are strengthening therapeutic development across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually expanding participation in ADHD research through healthcare modernization, greater involvement in multinational clinical trials, and stronger collaboration with global pharmaceutical organizations.

Competitive and Strategic Outlook

The global ADHD emerging therapies market is characterized by active participation from multinational pharmaceutical companies, biotechnology innovators, academic research institutions, and specialty neuroscience developers. Competition increasingly focuses on developing differentiated therapies that offer improved efficacy, enhanced safety, longer treatment duration, and reduced abuse potential.

Organizations are investing in artificial intelligence, biomarker discovery, precision medicine, digital therapeutics, and advanced drug delivery technologies to strengthen pipeline competitiveness. Strategic licensing agreements, research collaborations, mergers, acquisitions, and co-development partnerships continue to accelerate clinical development while reducing research risk.

Future competition is expected to focus on first-in-class mechanisms of action, personalized treatment strategies, long-acting formulations, digital health integration, and innovative therapeutic platforms capable of addressing the evolving needs of pediatric and adult ADHD patients.

Conclusion

The global ADHD emerging therapies market is expected to experience robust growth as innovation continues to transform the treatment landscape for attention deficit hyperactivity disorder. Rising diagnosis rates, expanding investment in neuroscience research, increasing development of non-stimulant therapies, technological advances in digital health, and adoption of precision medicine are expected to drive sustained market expansion. Although lengthy clinical development timelines, regulatory complexity, and high research costs remain important challenges, continued scientific innovation and strategic collaboration are expected to accelerate the introduction of safer, more effective, and more personalized ADHD therapies.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Emerging Therapy Landscape Overview
• 1.4 Commercial Opportunity Assessment
• 1.5 Key Growth Drivers and Challenges
• 1.6 Future Outlook for ADHD Therapeutics

2. Disease & Epidemiology Analysis

• 2.1 Overview of Attention Deficit Hyperactivity Disorder (ADHD)
  • 2.1.1 Definition and Clinical Characteristics
  • 2.1.2 Disease Burden and Unmet Needs
  • 2.1.3 Etiology and Risk Factors
  • 2.1.4 Neurobiological Basis of ADHD
• 2.2 Disease Classification
  • 2.2.1 Predominantly Inattentive Presentation
  • 2.2.2 Predominantly Hyperactive-Impulsive Presentation
  • 2.2.3 Combined Presentation
• 2.3 Signs and Symptoms
• 2.4 Diagnosis and Screening Guidelines
  • 2.4.1 Diagnostic Criteria
  • 2.4.2 Rating Scales and Assessment Tools
• 2.5 Epidemiology Analysis
  • 2.5.1 Prevalence by Age Group
  • 2.5.2 Prevalence by Gender
  • 2.5.3 Diagnosed vs Undiagnosed Population
  • 2.5.4 Epidemiological Trends and Forecast
• 2.6 Comorbidities Associated with ADHD
  • 2.6.1 Anxiety Disorders
  • 2.6.2 Depression
  • 2.6.3 Autism Spectrum Disorder
  • 2.6.4 Learning Disabilities
  • 2.6.5 Sleep Disorders

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Increasing ADHD Diagnosis Rates
  • 3.2.2 Growing Awareness and Early Screening
  • 3.2.3 Expanding Adult ADHD Treatment Market
  • 3.2.4 Advancements in Novel Therapeutic Modalities
• 3.3 Market Restraints
  • 3.3.1 Safety Concerns Related to Stimulants
  • 3.3.2 Drug Abuse and Dependence Risks
  • 3.3.3 Regulatory Challenges
• 3.4 Market Opportunities
  • 3.4.1 Non-Stimulant Drug Development
  • 3.4.2 Digital Therapeutics and Combination Approaches
  • 3.4.3 Precision Medicine Opportunities
• 3.5 Porter's Five Forces Analysis
• 3.6 PESTLE Analysis
• 3.7 Value Chain Analysis

4. Commercial & Market Access

• 4.1 Commercial Landscape Overview
• 4.2 Pricing Analysis
• 4.3 Reimbursement Landscape
  • 4.3.1 Public Reimbursement
  • 4.3.2 Private Insurance Coverage
• 4.4 Market Access Challenges
• 4.5 Generic Competition and Patent Expiry Analysis
• 4.6 Patient Assistance Programs
• 4.7 Distribution and Supply Chain Assessment

5. Innovation & Pipeline Landscape

• 5.1 Innovation Trends in ADHD Therapeutics
• 5.2 Emerging Treatment Modalities
  • 5.2.1 Novel Stimulants
  • 5.2.2 Non-Stimulant Therapies
  • 5.2.3 Extended-Release Formulations
  • 5.2.4 Transdermal Drug Delivery Systems
  • 5.2.5 Digital Therapeutics
• 5.3 Pipeline Analysis by Clinical Stage
  • 5.3.1 Discovery and Preclinical Stage
  • 5.3.2 Phase I Pipeline
  • 5.3.3 Phase II Pipeline
  • 5.3.4 Phase III Pipeline
• 5.4 Pipeline Analysis by Mechanism of Action
  • 5.4.1 Dopamine and Norepinephrine Reuptake Inhibitors
  • 5.4.2 Triple Reuptake Inhibitors
  • 5.4.3 Selective Norepinephrine Reuptake Inhibitors
  • 5.4.4 Monoamine Modulators
  • 5.4.5 Novel CNS Targets
• 5.5 Pipeline Analysis by Modality
  • 5.5.1 Small Molecules
  • 5.5.2 Drug Delivery Technologies
  • 5.5.3 Digital Therapeutics
• 5.6 Clinical Trial Landscape
• 5.7 Licensing, Collaborations, and Strategic Partnerships

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Pharmacological Treatment Overview
• 6.3 Stimulant Therapies
  • 6.3.1 Amphetamine-Based Therapies
  • 6.3.2 Methylphenidate-Based Therapies
• 6.4 Non-Stimulant Therapies
  • 6.4.1 Atomoxetine-Based Therapies
  • 6.4.2 Viloxazine-Based Therapies
  • 6.4.3 Alpha-2 Adrenergic Agonists
• 6.5 Approved ADHD Drugs Analysis
  • 6.5.1 Brand and Generic Overview
  • 6.5.2 Safety and Efficacy Comparison
  • 6.5.3 Dosage Forms and Administration
• 6.6 Non-Pharmacological Therapies
  • 6.6.1 Behavioral Therapy
  • 6.6.2 Cognitive Behavioral Therapy
  • 6.6.3 Parent Training Programs
  • 6.6.4 Educational Interventions
• 6.7 Treatment Algorithm and Clinical Guidelines

7. Global Attention Deficit Hyperactivity Disorder (ADHD) Emerging Therapies Report Size & Forecast

• 7.1 Global Market Overview
• 7.2 Historical Market Size Analysis
• 7.3 Forecast Market Size Analysis
• 7.4 Market Forecast by Therapy Type
• 7.5 Market Forecast by Route of Administration
• 7.6 Market Forecast by Distribution Channel
• 7.7 Market Forecast by End User
• 7.8 Emerging Therapies Market Opportunity Assessment

8. Global Attention Deficit Hyperactivity Disorder (ADHD) Emerging Therapies Report Segmentation

• 8.1 By Drug Class
  • 8.1.1 Stimulants
    • 8.1.1.1 Amphetamine-Based Drugs
    • 8.1.1.2 Methylphenidate-Based Drugs
  • 8.1.2 Non-Stimulants
    • 8.1.2.1 Selective Norepinephrine Reuptake Inhibitors
    • 8.1.2.2 Alpha-2 Adrenergic Agonists
• 8.2 By Age Group
  • 8.2.1 Pediatric & Adolescent ADHD
  • 8.2.2 Adult ADHD
• 8.3 By Route of Administration
  • 8.3.1 Oral
  • 8.3.2 Transdermal
• 8.4 By End User
  • 8.4.1 Hospitals
  • 8.4.2 Specialty Clinics
  • 8.4.3 Homecare Settings
• 8.5 By Distribution Channel
  • 8.5.1 Hospital Pharmacies
  • 8.5.2 Retail Pharmacies
  • 8.5.3 Online Pharmacies

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Market Size and Forecast
  • 9.1.2 Demand Drivers
  • 9.1.3 Regional Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Forecast
  • 9.2.2 Demand Drivers
  • 9.2.3 Regional Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Forecast
  • 9.3.2 Demand Drivers
  • 9.3.3 Regional Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Forecast
  • 9.4.2 Demand Drivers
  • 9.4.3 Regional Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Forecast
  • 9.5.2 Demand Drivers
  • 9.5.3 Regional Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Epidemiology
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement Scenario
  • 10.1.5 Key Companies and Products Presence
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Global Regulatory Overview
• 11.2 United States Regulatory Framework
  • 11.2.1 FDA Approval Pathways
  • 11.2.2 Controlled Substance Regulations
• 11.3 Europe Regulatory Framework
  • 11.3.1 EMA Regulations
  • 11.3.2 Controlled Drug Policies
• 11.4 Japan Regulatory Framework
  • 11.4.1 PMDA Approval Process
• 11.5 India Regulatory Framework
  • 11.5.1 CDSCO Approval Process
• 11.6 China Regulatory Framework
  • 11.6.1 NMPA Approval Process
• 11.7 Intellectual Property and Patent Landscape
• 11.8 Pharmacovigilance Requirements

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Portfolio Analysis
• 12.4 Pipeline Competitiveness Assessment
• 12.5 Strategic Developments
  • 12.5.1 Mergers and Acquisitions
  • 12.5.2 Licensing Agreements
  • 12.5.3 Collaborations and Partnerships
  • 12.5.4 Product Launches
• 12.6 SWOT Analysis

13. Company Profiles

• 13.1 Takeda Pharmaceutical Company
  • 13.1.1 Company Overview
  • 13.1.2 Approved ADHD Products: Vyvanse (lisdexamfetamine), Adderall XR (mixed amphetamine salts)
  • 13.1.3 Key Indications
  • 13.1.4 Pipeline and Strategic Focus
  • 13.1.5 Recent Developments
• 13.2 Eli Lilly and Company
  • 13.2.1 Company Overview
  • 13.2.2 Approved ADHD Products: Strattera (atomoxetine)
  • 13.2.3 Key Indications
  • 13.2.4 Pipeline and Strategic Focus
  • 13.2.5 Recent Developments
• 13.3 Supernus Pharmaceuticals
  • 13.3.1 Company Overview
  • 13.3.2 Approved ADHD Products: Qelbree (viloxazine extended-release)
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline and Strategic Focus
  • 13.3.5 Recent Developments
• 13.4 Corium LLC
  • 13.4.1 Company Overview
  • 13.4.2 Approved ADHD Products: Azstarys (serdexmethylphenidate/dexmethylphenidate), Jornay PM (methylphenidate)
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline and Strategic Focus
  • 13.4.5 Recent Developments
• 13.5 Noven Pharmaceuticals
  • 13.5.1 Company Overview
  • 13.5.2 Approved ADHD Products: Daytrana (methylphenidate transdermal system)
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline and Strategic Focus
  • 13.5.5 Recent Developments
• 13.6 Azurity Pharmaceuticals
  • 13.6.1 Company Overview
  • 13.6.2 Approved ADHD Products: Xelstrym (dextroamphetamine transdermal system)
  • 13.6.3 Key Indications
  • 13.6.4 Pipeline and Strategic Focus
  • 13.6.5 Recent Developments
• 13.7 Aytu BioPharma
  • 13.7.1 Company Overview
  • 13.7.2 Approved ADHD Products: Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate)
  • 13.7.3 Key Indications
  • 13.7.4 Pipeline and Strategic Focus
  • 13.7.5 Recent Developments
• 13.8 Tris Pharma
  • 13.8.1 Company Overview
  • 13.8.2 Approved ADHD Products: Quillivant XR, QuilliChew ER, Dyanavel XR
  • 13.8.3 Key Indications
  • 13.8.4 Pipeline and Strategic Focus
  • 13.8.5 Recent Developments
• 13.9 Arbor Pharmaceuticals
  • 13.9.1 Company Overview
  • 13.9.2 Approved ADHD Products: Evekeo, Evekeo ODT
  • 13.9.3 Key Indications
  • 13.9.4 Pipeline and Strategic Focus
  • 13.9.5 Recent Developments
• 13.10 Zevra Therapeutics
  • 13.10.1 Company Overview
  • 13.10.2 ADHD Product and Licensing Portfolio
  • 13.10.3 Key Indications
  • 13.10.4 Pipeline and Strategic Focus
  • 13.10.5 Recent Developments

14. Future Outlook

• 14.1 Future Market Trends
• 14.2 Emerging Technologies
• 14.3 Novel Mechanisms of Action
• 14.4 Opportunities in Adult ADHD
• 14.5 Future Competitive Scenario
• 14.6 Long-Term Market Forecast

15. Methodology

• 15.1 Research Objectives
• 15.2 Research Design
• 15.3 Primary Research Methodology
• 15.4 Secondary Research Methodology
• 15.5 Data Validation and Triangulation
• 15.6 Forecasting Methodology
• 15.7 Assumptions and Limitations
• 15.8 Abbreviations and Definitions